This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This study is no longer recruiting subjects.(from www.ClinicalTrials.gov website)Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Triapine (3-AP) may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help doxorubicin kill more cancer cells by making them more sensitive to the drug.This Phase I trial is studying the side-effects and best dose of triapine and doxorubicin in treating patients with metastatic or refractory solid tumors.
Showing the most recent 10 out of 459 publications